Epidermal growth factor receptor gene analysis with a highly sensitive molecular assay in routine cytologic specimens of lung adenocarcinoma

Sara Allegrini, Jlenia Antona, Rosanna Mezzapelle, Umberto Miglio, Alessia Paganotti, Claudia Veggiani, Milo Frattini, Guido Monga, Piero Balbo, Renzo Boldorini

Research output: Contribution to journalArticle

Abstract

Epidermal growth factor receptor (EGFR) gene mutational analysis is critical for guiding the treatment of lung adenocarcinoma. In everyday clinical practice, EGFR testing is frequently centralized in referral laboratories that may receive paucicellular cytologic specimens, often fixed in various ways. We conducted a search for EGFR mutations in 108 cytologic samples of lung adenocarcinoma from different hospitals using the TheraScreen EGFR29 kit. These samples included 80 (74.1%) fine-needle aspirations, 13 (12%) pleural/ascitic fluids, 13 (12%) bronchial washings, and 2 bronchial brushings. The samples were fixed in ethanol (n = 79), Duboscq-Brasil (n = 18) or formalin (n = 10); 1 was unfixed. Ninety-two (85.2%) were amplified, 16 (14.8%) were not. Mutations were detected in 22 (23.9%) of 92 amplified samples, 9 containing less than 200 cancer cells, and 4 with less than 50% cancer cells. DNA was amplified in 12 of 18 Duboscq-Brasil-fixed samples. These findings indicate that cytologic specimens are adequate for EGFR testing when a highly sensitive assay is used, even if they are paucicellular or not optimally fixed.

Original languageEnglish
Pages (from-to)377-381
Number of pages5
JournalAmerican Journal of Clinical Pathology
Volume138
Issue number3
DOIs
Publication statusPublished - Sep 2012

Fingerprint

erbB-1 Genes
Epidermal Growth Factor Receptor
Mutation
Ascitic Fluid
Fine Needle Biopsy
Formaldehyde
Neoplasms
Ethanol
Referral and Consultation
DNA
Adenocarcinoma of lung
Therapeutics

Keywords

  • Cytology
  • EGFR
  • Lung adenocarcinoma
  • Mutation analysis

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Epidermal growth factor receptor gene analysis with a highly sensitive molecular assay in routine cytologic specimens of lung adenocarcinoma. / Allegrini, Sara; Antona, Jlenia; Mezzapelle, Rosanna; Miglio, Umberto; Paganotti, Alessia; Veggiani, Claudia; Frattini, Milo; Monga, Guido; Balbo, Piero; Boldorini, Renzo.

In: American Journal of Clinical Pathology, Vol. 138, No. 3, 09.2012, p. 377-381.

Research output: Contribution to journalArticle

Allegrini, S, Antona, J, Mezzapelle, R, Miglio, U, Paganotti, A, Veggiani, C, Frattini, M, Monga, G, Balbo, P & Boldorini, R 2012, 'Epidermal growth factor receptor gene analysis with a highly sensitive molecular assay in routine cytologic specimens of lung adenocarcinoma', American Journal of Clinical Pathology, vol. 138, no. 3, pp. 377-381. https://doi.org/10.1309/AJCPVAGIUC1AHC3Y
Allegrini, Sara ; Antona, Jlenia ; Mezzapelle, Rosanna ; Miglio, Umberto ; Paganotti, Alessia ; Veggiani, Claudia ; Frattini, Milo ; Monga, Guido ; Balbo, Piero ; Boldorini, Renzo. / Epidermal growth factor receptor gene analysis with a highly sensitive molecular assay in routine cytologic specimens of lung adenocarcinoma. In: American Journal of Clinical Pathology. 2012 ; Vol. 138, No. 3. pp. 377-381.
@article{1640c6170f7c4f4daafe0b8d3ae1dba5,
title = "Epidermal growth factor receptor gene analysis with a highly sensitive molecular assay in routine cytologic specimens of lung adenocarcinoma",
abstract = "Epidermal growth factor receptor (EGFR) gene mutational analysis is critical for guiding the treatment of lung adenocarcinoma. In everyday clinical practice, EGFR testing is frequently centralized in referral laboratories that may receive paucicellular cytologic specimens, often fixed in various ways. We conducted a search for EGFR mutations in 108 cytologic samples of lung adenocarcinoma from different hospitals using the TheraScreen EGFR29 kit. These samples included 80 (74.1{\%}) fine-needle aspirations, 13 (12{\%}) pleural/ascitic fluids, 13 (12{\%}) bronchial washings, and 2 bronchial brushings. The samples were fixed in ethanol (n = 79), Duboscq-Brasil (n = 18) or formalin (n = 10); 1 was unfixed. Ninety-two (85.2{\%}) were amplified, 16 (14.8{\%}) were not. Mutations were detected in 22 (23.9{\%}) of 92 amplified samples, 9 containing less than 200 cancer cells, and 4 with less than 50{\%} cancer cells. DNA was amplified in 12 of 18 Duboscq-Brasil-fixed samples. These findings indicate that cytologic specimens are adequate for EGFR testing when a highly sensitive assay is used, even if they are paucicellular or not optimally fixed.",
keywords = "Cytology, EGFR, Lung adenocarcinoma, Mutation analysis",
author = "Sara Allegrini and Jlenia Antona and Rosanna Mezzapelle and Umberto Miglio and Alessia Paganotti and Claudia Veggiani and Milo Frattini and Guido Monga and Piero Balbo and Renzo Boldorini",
year = "2012",
month = "9",
doi = "10.1309/AJCPVAGIUC1AHC3Y",
language = "English",
volume = "138",
pages = "377--381",
journal = "American Journal of Clinical Pathology",
issn = "0002-9173",
publisher = "American Society of Clinical Pathologists",
number = "3",

}

TY - JOUR

T1 - Epidermal growth factor receptor gene analysis with a highly sensitive molecular assay in routine cytologic specimens of lung adenocarcinoma

AU - Allegrini, Sara

AU - Antona, Jlenia

AU - Mezzapelle, Rosanna

AU - Miglio, Umberto

AU - Paganotti, Alessia

AU - Veggiani, Claudia

AU - Frattini, Milo

AU - Monga, Guido

AU - Balbo, Piero

AU - Boldorini, Renzo

PY - 2012/9

Y1 - 2012/9

N2 - Epidermal growth factor receptor (EGFR) gene mutational analysis is critical for guiding the treatment of lung adenocarcinoma. In everyday clinical practice, EGFR testing is frequently centralized in referral laboratories that may receive paucicellular cytologic specimens, often fixed in various ways. We conducted a search for EGFR mutations in 108 cytologic samples of lung adenocarcinoma from different hospitals using the TheraScreen EGFR29 kit. These samples included 80 (74.1%) fine-needle aspirations, 13 (12%) pleural/ascitic fluids, 13 (12%) bronchial washings, and 2 bronchial brushings. The samples were fixed in ethanol (n = 79), Duboscq-Brasil (n = 18) or formalin (n = 10); 1 was unfixed. Ninety-two (85.2%) were amplified, 16 (14.8%) were not. Mutations were detected in 22 (23.9%) of 92 amplified samples, 9 containing less than 200 cancer cells, and 4 with less than 50% cancer cells. DNA was amplified in 12 of 18 Duboscq-Brasil-fixed samples. These findings indicate that cytologic specimens are adequate for EGFR testing when a highly sensitive assay is used, even if they are paucicellular or not optimally fixed.

AB - Epidermal growth factor receptor (EGFR) gene mutational analysis is critical for guiding the treatment of lung adenocarcinoma. In everyday clinical practice, EGFR testing is frequently centralized in referral laboratories that may receive paucicellular cytologic specimens, often fixed in various ways. We conducted a search for EGFR mutations in 108 cytologic samples of lung adenocarcinoma from different hospitals using the TheraScreen EGFR29 kit. These samples included 80 (74.1%) fine-needle aspirations, 13 (12%) pleural/ascitic fluids, 13 (12%) bronchial washings, and 2 bronchial brushings. The samples were fixed in ethanol (n = 79), Duboscq-Brasil (n = 18) or formalin (n = 10); 1 was unfixed. Ninety-two (85.2%) were amplified, 16 (14.8%) were not. Mutations were detected in 22 (23.9%) of 92 amplified samples, 9 containing less than 200 cancer cells, and 4 with less than 50% cancer cells. DNA was amplified in 12 of 18 Duboscq-Brasil-fixed samples. These findings indicate that cytologic specimens are adequate for EGFR testing when a highly sensitive assay is used, even if they are paucicellular or not optimally fixed.

KW - Cytology

KW - EGFR

KW - Lung adenocarcinoma

KW - Mutation analysis

UR - http://www.scopus.com/inward/record.url?scp=84865440963&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865440963&partnerID=8YFLogxK

U2 - 10.1309/AJCPVAGIUC1AHC3Y

DO - 10.1309/AJCPVAGIUC1AHC3Y

M3 - Article

C2 - 22912354

AN - SCOPUS:84865440963

VL - 138

SP - 377

EP - 381

JO - American Journal of Clinical Pathology

JF - American Journal of Clinical Pathology

SN - 0002-9173

IS - 3

ER -